In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to ...

Janssen opted not to continue with the first two integrin targets at the end of 2021 ... The collaboration was focused on development of alpha V beta 6 drugs for fibrotic diseases, including ...

an FDA-approved small molecule integrin antagonist currently used in dry eye treatment. Results showed the drug effectively suppressed lesion growth when administered in an endometriosis mouse ...

This year, it has been joined by natalizumab (Tysabri; Elan/Biogen-Idec), a humanized antibody against α4 integrin ... and the drug label contains a black-box warning of the risk of serious ...

No head-to-head trials exist and a prior comparison of the drugs' respective clinical trial ... with 141 patients taking the integrin receptor antagonist vedolizumab and 156 patients taking ...

Telix Pharma completes acquisition of next-generation therapeutic assets & innovative biologics technology platform of ImaginAb: Melbourne, Australia Saturday, February 1, 2025, 1 ...

anti-VEGF agent by binding to integrin receptors; and transferrin, which targets the drug to the choroid and retina by binding transferrin receptors on endothelial cells. These features will ...

The purchased drug candidates can be described as ‘next ... high-grade neuroendocrine tumors and small-cell lung cancer, and integrin αvβ6, which is overexpressed during wound healing and ...

This transaction adds a pipeline of early-stage drug candidates against high-value targets including DLL3 [1] and integrin αvβ6 [2], as well as several other novel targets in discovery stage.